Information  X 
Enter a valid email address

LiDCO Group Plc (LID)

  Print      Mail a friend       Annual reports

Tuesday 24 April, 2018

LiDCO Group Plc

Capital Markets Day

RNS Number : 8398L
LiDCO Group Plc
24 April 2018

LiDCO Group Plc

("LiDCO" or the "Company")


Capital Markets Day


LiDCO (AIM: LID), the hemodynamic monitoring company, announces it will be holding a Capital Markets Day for investors on Wednesday 16 May 2018.


A presentation with be given by CEO Matt Sassone, who will provide an overview of the Company and where it is currently positioned. The afternoon will also feature presentations by:


·     Shane Doorish, Head of North America

Shane joined LiDCO in January 2017 bringing with him 19 years of experience in the healthcare sector having originally trained as a critical care nurse. This includes 12 years with Edwards Lifesciences, a major global provider of hemodynamic monitoring, where Shane held a number of sales and marketing positions.


·     Eric Mills, Head of Technology

Eric has been at LiDCO for over 14 years having overseen the transformation of the technology to its current non-invasive form. He has a wealth of expertise in the hemodynamic monitoring market.


·     Dr Max Jonas, Clinical Adviser

Dr Jonas is a Consultant Intensivist, Senior Lecturer and Tutor in critical care working at Southampton University and Hospitals. He is currently a senior consultant on the 28 bed general intensive care unit and has specific interests in hemodynamics and health technology assessment. He is an elected member of the Council of the Intensive Care Society and has completed a six year term of the technology assessment section of the European Society of Intensive Care Medicine.


The event will be held at LiDCO's HQ, 16 Orsman Road, London, N1 5QJ at 4pm. This will be followed by light refreshments and an opportunity to talk to senior management further.


The presentation will be available on the Company website shortly after the event, and no new material or trading information will be provided.


To register, please email [email protected] or telephone Walbrook PR on the number below.





For further information, please contact:


Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303





About LiDCO Group Plc (

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 


Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.


Key Products:


LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring. Version 2 of this software is only available on a new slim widescreen monitor and includes the optional high usage program software in selected markets.


LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness.


LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:


·     early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·     quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time


The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 


LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.


*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.


LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 


LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.


LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t